Enhancing Action of Positive Allosteric Modulators through the Design of Dimeric Compounds

Thomas Drapier; Pierre Geubelle; Charlotte Bouckaert; Lise Nielsen; Saara Laulumaa; Eric Goffin; Sébastien Dilly; Pierre Francotte; Julien Hanson; Lionel Pochet; Jette Sandholm Kastrup; Bernard Pirotte

doi:10.1021/acs.jmedchem.8b00250

Enhancing Action of Positive Allosteric Modulators through the Design of Dimeric Compounds

Thomas Drapier, Pierre Geubelle, Charlotte Bouckaert, Lise Nielsen, Saara Laulumaa, Eric Goffin, Sébastien Dilly, Pierre Francotte, Julien Hanson, Lionel Pochet, Jette Sandholm Kastrup, Bernard Pirotte

18 Citations (Scopus)

Abstract

The present study describes the identification of highly potent dimeric 1,2,4-benzothiadiazine 1,1-dioxide (BTD)-type positive allosteric modulators of the AMPA receptors (AMPApams) obtained by linking two monomeric BTD scaffolds through their respective 6-positions. Using previous X-ray data from monomeric BTDs cocrystallized with the GluA2 ligand-binding domain (LBD), a molecular modeling approach was performed to predict the preferred dimeric combinations. Two 6,6-ethylene-linked dimeric BTD compounds (16 and 22) were prepared and evaluated as AMPApams on HEK293 cells expressing GluA2o( Q) (calcium flux experiment). These compounds were found to be about 10,000 times more potent than their respective monomers, the most active dimeric compound being the bis-4-cyclopropyl-substituted compound 22 [6,6'-(ethane-1,2-diyl)bis(4-cyclopropyl-3,4-dihydro-2 H-1,2,4-benzothiadiazine 1,1-dioxide], with an EC50 value of 1.4 nM. As a proof of concept, the bis-4-methyl-substituted dimeric compound 16 (EC50 = 13 nM) was successfully cocrystallized with the GluA2o-LBD and was found to occupy the two BTD binding sites at the LBD dimer interface.

Original language	English
Journal	Journal of Medicinal Chemistry
Volume	61
Issue number	12
Pages (from-to)	5279-5291
Number of pages	13
ISSN	0022-2623
DOIs	https://doi.org/10.1021/acs.jmedchem.8b00250
Publication status	Published - 28 Jun 2018

Access to Document

10.1021/acs.jmedchem.8b00250

Cite this

@article{c605274805de440b9967f60e9546e4f1,

title = "Enhancing Action of Positive Allosteric Modulators through the Design of Dimeric Compounds",

abstract = "The present study describes the identification of highly potent dimeric 1,2,4-benzothiadiazine 1,1-dioxide (BTD)-type positive allosteric modulators of the AMPA receptors (AMPApams) obtained by linking two monomeric BTD scaffolds through their respective 6-positions. Using previous X-ray data from monomeric BTDs cocrystallized with the GluA2 ligand-binding domain (LBD), a molecular modeling approach was performed to predict the preferred dimeric combinations. Two 6,6-ethylene-linked dimeric BTD compounds (16 and 22) were prepared and evaluated as AMPApams on HEK293 cells expressing GluA2o( Q) (calcium flux experiment). These compounds were found to be about 10,000 times more potent than their respective monomers, the most active dimeric compound being the bis-4-cyclopropyl-substituted compound 22 [6,6'-(ethane-1,2-diyl)bis(4-cyclopropyl-3,4-dihydro-2 H-1,2,4-benzothiadiazine 1,1-dioxide], with an EC50 value of 1.4 nM. As a proof of concept, the bis-4-methyl-substituted dimeric compound 16 (EC50 = 13 nM) was successfully cocrystallized with the GluA2o-LBD and was found to occupy the two BTD binding sites at the LBD dimer interface.",

author = "Thomas Drapier and Pierre Geubelle and Charlotte Bouckaert and Lise Nielsen and Saara Laulumaa and Eric Goffin and S{\'e}bastien Dilly and Pierre Francotte and Julien Hanson and Lionel Pochet and Kastrup, {Jette Sandholm} and Bernard Pirotte",

year = "2018",

month = jun,

day = "28",

doi = "10.1021/acs.jmedchem.8b00250",

language = "English",

volume = "61",

pages = "5279--5291",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "12",

}

TY - JOUR

T1 - Enhancing Action of Positive Allosteric Modulators through the Design of Dimeric Compounds

AU - Drapier, Thomas

AU - Geubelle, Pierre

AU - Bouckaert, Charlotte

AU - Nielsen, Lise

AU - Laulumaa, Saara

AU - Goffin, Eric

AU - Dilly, Sébastien

AU - Francotte, Pierre

AU - Hanson, Julien

AU - Pochet, Lionel

AU - Kastrup, Jette Sandholm

AU - Pirotte, Bernard

PY - 2018/6/28

Y1 - 2018/6/28

N2 - The present study describes the identification of highly potent dimeric 1,2,4-benzothiadiazine 1,1-dioxide (BTD)-type positive allosteric modulators of the AMPA receptors (AMPApams) obtained by linking two monomeric BTD scaffolds through their respective 6-positions. Using previous X-ray data from monomeric BTDs cocrystallized with the GluA2 ligand-binding domain (LBD), a molecular modeling approach was performed to predict the preferred dimeric combinations. Two 6,6-ethylene-linked dimeric BTD compounds (16 and 22) were prepared and evaluated as AMPApams on HEK293 cells expressing GluA2o( Q) (calcium flux experiment). These compounds were found to be about 10,000 times more potent than their respective monomers, the most active dimeric compound being the bis-4-cyclopropyl-substituted compound 22 [6,6'-(ethane-1,2-diyl)bis(4-cyclopropyl-3,4-dihydro-2 H-1,2,4-benzothiadiazine 1,1-dioxide], with an EC50 value of 1.4 nM. As a proof of concept, the bis-4-methyl-substituted dimeric compound 16 (EC50 = 13 nM) was successfully cocrystallized with the GluA2o-LBD and was found to occupy the two BTD binding sites at the LBD dimer interface.

AB - The present study describes the identification of highly potent dimeric 1,2,4-benzothiadiazine 1,1-dioxide (BTD)-type positive allosteric modulators of the AMPA receptors (AMPApams) obtained by linking two monomeric BTD scaffolds through their respective 6-positions. Using previous X-ray data from monomeric BTDs cocrystallized with the GluA2 ligand-binding domain (LBD), a molecular modeling approach was performed to predict the preferred dimeric combinations. Two 6,6-ethylene-linked dimeric BTD compounds (16 and 22) were prepared and evaluated as AMPApams on HEK293 cells expressing GluA2o( Q) (calcium flux experiment). These compounds were found to be about 10,000 times more potent than their respective monomers, the most active dimeric compound being the bis-4-cyclopropyl-substituted compound 22 [6,6'-(ethane-1,2-diyl)bis(4-cyclopropyl-3,4-dihydro-2 H-1,2,4-benzothiadiazine 1,1-dioxide], with an EC50 value of 1.4 nM. As a proof of concept, the bis-4-methyl-substituted dimeric compound 16 (EC50 = 13 nM) was successfully cocrystallized with the GluA2o-LBD and was found to occupy the two BTD binding sites at the LBD dimer interface.

U2 - 10.1021/acs.jmedchem.8b00250

DO - 10.1021/acs.jmedchem.8b00250

M3 - Journal article

C2 - 29775064

SN - 0022-2623

VL - 61

SP - 5279

EP - 5291

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 12

ER -

Enhancing Action of Positive Allosteric Modulators through the Design of Dimeric Compounds

Abstract

Access to Document

Fingerprint

Cite this